Johnson & Johnson Pharmaceutical Research & Development is committed to providing the media with timely and accurate information. This section offers key resources for journalists, editors and other media professionals. Members of the media should contact: glblpharmardcom@jnjprd.us.com or call 908.927.3753

Press Releases:

(02/04/2010) TAPENTADOL EXTENDED RELEASE DATA TO BE PRESENTED AT AMERICAN ACADEMY OF PAIN MEDICINE ANNUAL MEETING

(01/11/2010) Nominations Open for The 2010 Dr. Paul Janssen Award for Biomedical Research

(12/30/2009) FDA Issues Complete Response Letter for Ceftobiprole

(12/06/2009) Phase III Study of Rivaroxaban Shows That Extending Anticoagulant Treatment by Six or 12 Months Significantly Reduced Risk of Second Symptomatic VTE

(12/01/2009) NEW DRUG APPLICATION SUBMITTED TO FDA FOR TAPENTADOL EXTENDED RELEASE TABLETS FOR MANAGEMENT OF CHRONIC PAIN.

(09/17/2009) Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimer's Immunotherapy Program and Equity Investment.

(09/08/2009) Johnson & Johnson Honors 2009 Recipient of The Dr. Paul Janssen Award for Biomedical Research.

(07/31/2009) FDA Approves INVEGA^® SUSTENNA^™ for the Acute and Maintenance Treatment of Schizophrenia.

(07/02/2009) Johnson & Johnson and Elan Corporation plc Announce Definitive Agreement for Alzheimer's Immunotherapy Program and Equity Investment.

(06/22/2009) NUCYNTA™ Launches in the United States: Milestone for Pain Franchise

(05/19/2009) New Data Demonstrate RISPERDAL^® CONSTA^® (Risperidone) Long-Acting Treatment May Improve Health Outcomes and Reduce Hospitalizations in Patients with Schizophrenia

(03/19/2009) CENTOCOR R&D AND UNIVERSITY OF MICHIGAN FORGE NEW MODEL FOR ACADEMIC/INDUSTRY PARTNERSHIPS

(02/11/2009) PREZISTA® Now Available for Pediatric Patients Six Years of Age and Older as part of HIV Combination Therapy

(02/10/2009) FDA Issues Complete Response Letter for RISPERDAL® CONSTA® for the Adjunctive Maintenance Treatment of Bipolar Disorder

(02/10/2009) Priligy^TM (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) In Finland and Sweden

(02/09/2009) Launch Of STELARA®, Offers Psoriasis Patients Significant And Visible Results Maintained With Just Five Doses A Year

(02/06/2009) Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings For Paliperidone Palmitate And Invega®

(02/03/2009) Tibotec Submits Application to U.S. Food and Drug Administration Seeking Traditional Approval for Intelence^TM (Etravirine)

(02/03/2009) Once-Daily PREZISTA® (darunavir) For Treatment-Naive Adults with Hiv-1 Receives Approval in the European Union as Part of Combination Therapy

(01/22/2009) New Biologic Stelar^TM Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis

(11/26/2008) FDA Issues Complete Response Letter for Ceftobiprole for Treatment of Complicated Skin Infections

(11/21/2008) FDA Approves Tapentadol Immediate-Release Tablets for Relief of Moderate to Severe Acute Pain

(11/13/2008) New Antibiotic Against Serious Infections - Receives First Approval in Europe

(10/27/2008) New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria

(10/23/2008) Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate

(08/21/2008) FDA Requires Additional Information on DORIBAX™ for Treatment of Hospital-Acquired Pneumonia

(07/30/2008) Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Rivaroxaban

(07/16/2008) FDA Advisory Committee Provides Opinion of DORIBAX™ for the Treatment of Hospital-Acquired Pneumonia

(06/27/2008) FDA Approves CONCERTA® (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults

(06/25/2008) Results From Two Phase III Studies of Rivaroxaban Published in The New England Journal of Medicine

(06/25/2008) Results From Phase III Study of Rivaroxaban Published in The Lancet

(05/30/2008) Rivaroxaban Superior to U.S.-Approved Dosing Regimen for Enoxaparin in Reducing Venous Blood Clots after Total Knee Replacement Surgery in Pivotal Phase III Trial


(05/09/2008) Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile

(05/09/2008) New Study Suggests Tapentadol IR For Acute Pain is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR

(05/09/2008) New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective For Acute Pain From Common Foot Surgery

(05/07/2008) Seven Clinical Presentations on Tapentadol Immediate Release for Acute Pain to Be Featured at 2008 American Pain Society Annual Meeting

(03/18/2008) FDA Issues Approvable Letter for Ceftobiprole for Treatment of Complicated Skin Infections

(03/06/2008) FDA Extends Review Timeline for Additional Indication for Antibiotic DORIBAX™

(01/23/2008) New Drug Application Submitted to FDA for Investigational Analgesic Tapentadol Immediate Release Tablets

(12/10/2007) Three Phase III Trials Show Rivaroxaban Outperformed Enoxaparin in Preventing Venous Thromboembolism After Major Orthopedic Surgery

(12/08/2007) Pivotal Phase III Data Showed Rivaroxaban Was Statistically Superior to Enoxaparin in Preventing Venous Thromboembolism (VTE) in Patients Following Hip Replacement Surgery

(11/12/2007) New Phase III Trial Results for Rivaroxaban to be Presented at the 49th Annual Meeting of the American Society of Hematology

(10/29/2007) Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate

(09/18/2007) New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias

(09/18/2007) New Data Show Ceftobiprole as Effective as Combination Therapy in Treating Patients with Complicated Skin Infections, Including MRSA

(06/21/2007) FDA Issues Approvable Letter for RISPERDAL® to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania

(06/06/2007) New Drug Application Submitted For Investigational Antibiotic Doripenem

(05/18/2007) New Drug Application Submitted For Novel Investigational Antibiotic Ceftobiprole

(05/08/2007) Janssen-Cilag and Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) Open New Facility in Mumbai